Davis,
You may be right. Most of us who have been following and trading biotechs and smaller pharmas from way back know that these stocks had often spiked with some good hype, and then fell back with reality. I'm not disappointed that TCLN shares are trading this low, or that investors have been ignoring the stock. What is key, of course, is the reality. If TCLN does demonstrate commercial capabilities that eminate from their science, the stock will perform as it should. To have a stock price reflect the far off potential performance of the company is not necessarily good or healthy unless the likelihood of success is generally accepted.
You can trace success stories like Medimmune and see the ups and downs of a company over the past 4 years or more. HIV and CORR have made nice moves up on hype and promise, but they could be riding high in August and shot down in May.
I have been picking up small holding in "speculative" biotechs over many years figuring that if 1 in 5 makes it big, then I'm happy. Risks are higher, and so are the rewards. TCLN to me is still risky, but it appears that once the positives Davis and others have alluded to come out, TCLN should be postioned to succeed. As far as the speculation as to where the price can go, let's not be too greedy. I'm sure TCLN can make us all happy - particularly the long-term investor who truly deserve a reward for their patience.
Good Luck,
Shep |
